Value of alkaline phosphatase assay in short stature exploration


Pediatric Department, University Hospital of Rouen, Rouen, France
Pediatric competence centre for rare endocrine diseases including rare disorders of calcium and phosphorus
alexandre.naccache@chu-rouen.fr

ABSTRACT

Background: Short stature is a common reason for pediatric endocrinologist consultation, but in many cases, no cause can be identified. Childhood hypophosphatasia has widely variable clinical features from short stature to low bone mineral density with skeletal deformities, and the place of serum alkaline phosphatase (ALP) activity assay could be raised as an etiological exploration is not consensual.

Objectives and hypotheses: The aim of our study was to evaluate the ALP levels in a cohort of short stature children.

Methods: Children referred in our teaching hospital of Rouen for evaluation of short stature (height < -2 SD, or decreased growth velocity greater than 1 SD) from the 1st January 2010 to the 31th December 2014 were included in the present retrospective study. Children were eligible when a growth hormone stimulation test and an ALP assay were performed. Anamnestic, anatomic, urologic, biological and radiological data were collected.

Results: 167 children (101 boys, and 66 girls) were included at a mean age referral of 8.6 years old (0.5-18) with a mean height at -2.4 SD [-5.05]. Whereas the majority of patients revealed normal ALP level, 11 showed low ALP levels (i.e. -120 U/l) (67-129), among whom 4 had a somatostatin deficiency. None of them demonstrated radiological abnormalities or skeletal deformations. 7 among the 11 patients had a second ALP assay revealing for 6 of them normal ALP level, mostly concomitant with an acceleration of growth velocity. No controls were available up to now for the others children.

Conclusion: Abnormal ALP activity was observed in 6.3% studied patients suggesting that hypophosphatasia could be a new cause of short stature and that ALP assay need to be performed until further studies in larger population confirm this hypothesis.

AIM OF THE STUDY

We aimed to analyze the different causes of short stature including the possible hypophosphatasia hypothesis through systematic measurement of ALP assay to determine whether hypophosphatasia could be a cause of short stature.

PATIENTS AND METHOD

Monocentric Retrospective Observational Study

We included children referred in our hospital for evaluation from the 1st January 2010 to the 31th December 2014 with these criteria:

Inclusion criteria:
- Height < -2 DS
- and/or decreased growth velocity greater than 1 SD
- and/or delta between height and genetic height > 2 SDS
- with measures of ALP assay and growth hormone stimulation test

Exclusion criteria:
- Hepatic impairment that may interfere with ALP assay

We recorded following data at the time of the exploration:
- Anamnestic: parental height, history of SGA, known chronic disease
- Axological and clinical: age, sex, weight, Tanner stage, dysmorphic features
- Biological: IGF1, GH stimulation test, TSH, T4, ACTH, cortisol, CBC, ALP level
- Radiological: Bone age, and skeletal X-ray if available

We defined low ALP level if < 120 U/l

CONCLUSION AND PERSPECTIVES

☐ Abnormal ALP activity was observed in 11 out of the 137 children studied (6.5%), suggesting that hypophosphatasia could be a rare cause of short stature.

☐ However, a large majority of children with low ALP level at first evaluation showed either normal ALP level at control (likely attributable to increase height velocity) or normal skeletal X-ray, that makes the diagnosis of hypophosphatasia unlikely.

☐ Further studies with systematic ALP assay need to be performed to determine whether hypophosphatasia could be a cause of short stature.

REFERENCES


DOI: 10.3252/pso.eu.54espe.2015
Poster presented at: Growth 2016